Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
RESEARCH TRIANGLE PARK, N.C. - IQVIA (NYSE:IQV), a prominent player in the Life Sciences Tools & Services industry with a market capitalization of $27.6 billion, has introduced new custom-built AI agents at GTC Paris that utilize NVIDIA technology to enhance workflows and accelerate insights for life sciences companies, according to a press release statement. According to InvestingPro data, the company generates annual revenue of $15.5 billion.
The AI agents leverage NVIDIA NIM Agent Blueprints for development, NeMo Customizer for fine-tuning, and NeMo Guardrails for deployment safety. Applications include target identification, clinical data review, literature review, market assessment, and healthcare professional engagement.
"This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnerships," said Bhavik Patel, president of IQVIA Commercial Solutions.
The development follows a strategic collaboration announced in January between IQVIA and NVIDIA to build custom foundation models and AI workflows to accelerate research, clinical development, and access to new treatments. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with 15 analysts providing coverage of the company.
Kimberly Powell, vice president of healthcare at NVIDIA, noted that the collaboration aims to build domain-specific agents demonstrating efficiency and precision, with one example being AI assistance for literature reviews.
IQVIA, which employs approximately 88,000 people in over 100 countries, provides clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries. The company will showcase more developments at its TechIQ 2025 conference in London this September. The stock has shown significant momentum with an 8% return over the last week, and detailed analysis is available in the comprehensive Pro Research Report on InvestingPro, which covers over 1,400 US stocks.
In other recent news, IQVIA Holdings Inc. reported its first-quarter 2025 earnings, demonstrating a strong financial performance. The company achieved an adjusted earnings per share (EPS) of $2.70, surpassing the forecast of $2.64, and reported revenue of $3.83 billion, exceeding the expected $3.78 billion. IQVIA also raised its full-year revenue guidance to a range of $16.0 to $16.4 billion. Additionally, IQVIA has priced a $2 billion offering of senior notes due in 2032, with proceeds earmarked for repaying existing borrowings and general corporate purposes. The offering is set to close soon, subject to customary conditions. Despite these positive financial results, IQVIA’s stock experienced a slight decline in pre-market trading. The company also continues to expand its AI capabilities and strategic partnerships, which are anticipated to support future performance. Furthermore, IQVIA’s strategic financial moves aim to enhance its global reach and solution portfolio in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.